...
首页> 外文期刊>Circulation journal >Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME (R)
【24h】

Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME (R)

机译:Empagliflozin和亚洲患者患有2型糖尿病患者的心血管结果和成立的心血管疾病 - 结果来自EMPA-REG结果(R)

获取原文
获取原文并翻译 | 示例
           

摘要

Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race.
机译:背景:在EMPA-REG结果(R)试验中,Empagliflozin添加到护理标准降低了3点主要不良心血管(CV)事件的风险(3点均:CV死亡,非致命心肌梗死的复合, 或非致命中风)在2型糖尿病(T2DM)(T2DM)和建立的CV疾病患者和建立CV疾病的患者中,心力衰竭的38%,心力衰竭38%,心力衰竭35%,均导致死亡率为32%。 我们调查了Empagliflozin在亚洲赛患者中的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号